SCHEMBL4086482

SCHEMBL4086482

CC(O)c1cccc(NC(=O)NC(c2ccc(C(=O)Nc3nn[nH]n3)cc2)c2ccc(C3CCCCC3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 6/20 0.44
LMNA P02545 2/20 0.43
NAMPT P43490 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CCKBR P32239 2/20 0.39
GIPR P48546 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
DEGS1 O15121 1/20 0.37
GLP1R P43220 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
SIRT3 Q9NTG7 1/20 0.37
ADCY6 O43306 1/20 0.36
ADCY3 O60266 1/20 0.36
ADCY9 O60503 1/20 0.36
ADCY5 O95622 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087662 0.90 GCGR (0.46) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4081953 0.88 GCGR (0.49) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4081849 0.88 GCGR (0.44) GCGRLMNANAMPTMEN1KMT2A
SCHEMBL4091638 0.88 GCGR (0.44) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4091670 0.88 GCGR (0.43) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4085175 0.88 GCGR (0.43) GCGRLMNANAMPTMEN1KMT2A
SCHEMBL4085344 0.87 GCGR (0.46) GCGRGIPRADCY8ADCY1
SCHEMBL4095592 0.86 GCGR (0.45) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4086859 0.86 GCGR (0.43) GCGRLMNAGIPRHDAC3HDAC11
SCHEMBL4092780 0.86 GCGR (0.46) GCGRLMNANAMPTCCKBRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.